

## Cancer Institute of New Jersey



# Clinical Trials Connection

*A Cancer Resource for Healthcare Professionals*

June 2013

### [Resources for Physicians](#)

 [Send to a Colleague](#)

 [Join Our Mailing List](#)



**Rajat Bannerji,  
MD, PhD,**

is a hematologist/oncologist specializing in the evaluation and treatment of chronic leukemias and lymphomas and a member of the Blood and Marrow Transplant Program.

Contact Dr. Bannerji:  
[bannerra@umdnj.edu](mailto:bannerra@umdnj.edu)  
732-235-7996

### Clinical Trial Spotlight

**Drug Highlighted  
at ASCO Available  
at the Cancer  
Institute of New  
Jersey**

**Randomized, Phase II  
Study of MK-3475  
versus Chemotherapy  
in Patients with  
Advanced Melanoma**

The purpose of this study is to compare the overall response rate by week 12, progression-free-survival and overall survival of MK-3475

## Hematologic Malignancies Clinical Trials

[View all related clinical trials](#)

[View printable version](#)

### Randomized Trial Testing a Probiotic Enteric Regimen (Randomized PERFECT Trial)

The study aims to:

- Determine if allogeneic hematopoietic stem cell transplant patients treated with a probiotic containing diet compared to those not assigned to receive probiotic have a lower incidence of grade 1 upper GI or grade 2-4 lower GI acute GVHD using CIBMTR scoring than those not prescribed a probiotic.
- Determine if allogeneic hematopoietic stem cell transplant patients treated with a probiotic-containing diet compared to those not assigned to receive a probiotic have (a) lower rate of organ-specific GVHD; (b) lower rate of moderate to severe chronic GVHD at 6 months and 1 year post transplant; (c) shorter duration of immunosuppressive therapy; (d) lower rate of bacterial and/or opportunistic infection.

[Learn more about this trial](#)

### ECOG E2408: Three Bendamustine-Rituximab-based Combinations in Follicular Lymphoma

The study aims to:

- Compare the complete remission rate of Bendamustine-Rituximab (BR) versus Rituximab versus Bortezomib-BR (BVR) as induction therapy.
- Compare the one-year post-induction disease-free survival rate with rituximab plus lenalidomide to rituximab alone as continuation therapy.
- Determine the three-year progression-free survival and the five-year overall survival with BR, BVR, lenalidomide plus rituximab, and rituximab alone.

[Learn more about this trial](#)

### Phase II Study of Nuclear Factor-kappa B Inhibition During Induction Chemotherapy for AML

versus standard chemotherapy in patients with advanced melanoma.

[Learn more about this clinical trial](#)

## Other Available Trials

[Breast](#)

[Gynecologic](#)

[Thoracic](#)

[Melanoma](#)

[Prostate](#)

[Gastrointestinal](#)

[Pediatric](#)

[Phase I](#)



A Comprehensive Cancer Center Designated by the National Cancer Institute

The study aims to:

- Determine temporal changes in leukemic cell nuclear NF-kB activity when salicylate is administered to patients with AML during induction chemotherapy.
- Determine toxicities associated with administration of salicylate in the setting of induction chemotherapy.
- Determine if salicylate alters the expression of NF-kB regulated genes in AML cells.
- Determine if NF-kB modulation by salicylate alters AML chemotherapy drug efflux.

[Learn more about this trial](#)

---

## COG-AALL0434: Nelarabine in Children and Young Adults with Newly Diagnosed T Cell ALL or T Cell NHL

The study aims to:

- Determine, through randomization, the relative safety and efficacy of the addition of Nelarabine (Compound 506U78) to augmented BFM therapy (Regimen C, CCG-1961).
- Determine the relative safety and efficacy of high dose methotrexate (5gm/m<sup>2</sup>) with leucovorin rescue compared to escalating methotrexate without leucovorin rescue plus PEG-Asparaginase (Capizzi I) delivered during Interim Maintenance.
- Determine the relative safety and efficacy of withholding radiation in patients with low risk T-ALL, while treating intermediate and high-risk patients with 1200 cGy of prophylactic cranial radiation.

[Learn more about this trial](#)



As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, the Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute of New Jersey currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients. [Learn more](#)

---

[Forward this email](#)



This email was sent to vogeldl@umdnj.edu by [vogeldl@umdnj.edu](mailto:vogeldl@umdnj.edu) | [Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

The Cancer Institute of New Jersey | 195 Little Albany Street | New Brunswick | NJ | 08903